I-Mab (IMAB) shares were up more than 16% in recent Monday trading after the company said it will focus on advancing givastomig as its lead program targeting first-line metastatic gastric cancers, with further potential in other solid tumors.

A dose escalation study of givastomig with nivolumab plus chemotherapy has been completed, and the data are expected in the early second half of 2025, I-Mab said.

The biotech company said a dose expansion study involving 40 patients is underway, with data expected in early 2026.

I-Mab said its cash position would be able to fund the givastomig phase 1b study through dose expansion data readouts and further development plans into 2027.

Price: 1.07, Change: +0.16, Percent Change: +16.94